Cargando…

Patient-derived tumor models are attractive tools to repurpose drugs for ovarian cancer treatment: pre-clinical updates

Despite advances in understanding of ovarian cancer biology, the progress in translation of research findings into new therapies is still slow. It is associated in part with limitations of commonly used cancer models such as cell lines and genetically engineered mouse models that lack proper represe...

Descripción completa

Detalles Bibliográficos
Autores principales: Cybula, Magdalena, Bieniasz, Magdalena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959092/
https://www.ncbi.nlm.nih.gov/pubmed/35359749
http://dx.doi.org/10.18632/oncotarget.28220
_version_ 1784677073843912704
author Cybula, Magdalena
Bieniasz, Magdalena
author_facet Cybula, Magdalena
Bieniasz, Magdalena
author_sort Cybula, Magdalena
collection PubMed
description Despite advances in understanding of ovarian cancer biology, the progress in translation of research findings into new therapies is still slow. It is associated in part with limitations of commonly used cancer models such as cell lines and genetically engineered mouse models that lack proper representation of diversity and complexity of actual human tumors. In addition, the development of de novo anticancer drugs is a lengthy and expensive process. A promising alternative to new drug development is repurposing existing FDA-approved drugs without primary oncological purpose. These approved agents have known pharmacokinetics, pharmacodynamics, and toxicology and could be approved as anticancer drugs quicker and at lower cost. To successfully translate repurposed drugs to clinical application, an intermediate step of pre-clinical animal studies is required. To address challenges associated with reliability of tumor models for pre-clinical studies, there has been an increase in development of patient-derived xenografts (PDXs), which retain key characteristics of the original patient’s tumor, including histologic, biologic, and genetic features. The expansion and utilization of clinically and molecularly annotated PDX models derived from different ovarian cancer subtypes could substantially aid development of new therapies or rapid approval of repurposed drugs to improve treatment options for ovarian cancer patients.
format Online
Article
Text
id pubmed-8959092
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-89590922022-03-30 Patient-derived tumor models are attractive tools to repurpose drugs for ovarian cancer treatment: pre-clinical updates Cybula, Magdalena Bieniasz, Magdalena Oncotarget Review Despite advances in understanding of ovarian cancer biology, the progress in translation of research findings into new therapies is still slow. It is associated in part with limitations of commonly used cancer models such as cell lines and genetically engineered mouse models that lack proper representation of diversity and complexity of actual human tumors. In addition, the development of de novo anticancer drugs is a lengthy and expensive process. A promising alternative to new drug development is repurposing existing FDA-approved drugs without primary oncological purpose. These approved agents have known pharmacokinetics, pharmacodynamics, and toxicology and could be approved as anticancer drugs quicker and at lower cost. To successfully translate repurposed drugs to clinical application, an intermediate step of pre-clinical animal studies is required. To address challenges associated with reliability of tumor models for pre-clinical studies, there has been an increase in development of patient-derived xenografts (PDXs), which retain key characteristics of the original patient’s tumor, including histologic, biologic, and genetic features. The expansion and utilization of clinically and molecularly annotated PDX models derived from different ovarian cancer subtypes could substantially aid development of new therapies or rapid approval of repurposed drugs to improve treatment options for ovarian cancer patients. Impact Journals LLC 2022-03-24 /pmc/articles/PMC8959092/ /pubmed/35359749 http://dx.doi.org/10.18632/oncotarget.28220 Text en Copyright: © 2022 Cybula and Bieniasz. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Review
Cybula, Magdalena
Bieniasz, Magdalena
Patient-derived tumor models are attractive tools to repurpose drugs for ovarian cancer treatment: pre-clinical updates
title Patient-derived tumor models are attractive tools to repurpose drugs for ovarian cancer treatment: pre-clinical updates
title_full Patient-derived tumor models are attractive tools to repurpose drugs for ovarian cancer treatment: pre-clinical updates
title_fullStr Patient-derived tumor models are attractive tools to repurpose drugs for ovarian cancer treatment: pre-clinical updates
title_full_unstemmed Patient-derived tumor models are attractive tools to repurpose drugs for ovarian cancer treatment: pre-clinical updates
title_short Patient-derived tumor models are attractive tools to repurpose drugs for ovarian cancer treatment: pre-clinical updates
title_sort patient-derived tumor models are attractive tools to repurpose drugs for ovarian cancer treatment: pre-clinical updates
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959092/
https://www.ncbi.nlm.nih.gov/pubmed/35359749
http://dx.doi.org/10.18632/oncotarget.28220
work_keys_str_mv AT cybulamagdalena patientderivedtumormodelsareattractivetoolstorepurposedrugsforovariancancertreatmentpreclinicalupdates
AT bieniaszmagdalena patientderivedtumormodelsareattractivetoolstorepurposedrugsforovariancancertreatmentpreclinicalupdates